The potent effects of fascin upregulation has motivated the development of small-molecule fascin inhibitors, which have shown promise as cancer therapeutics in preclinical mouse models and are undergoing phase 2 clinical trials for treatment of gynecological and breast cancers42–44. Here, FSCN1 is linked to medical procedure.